• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

aMoon II Raises $600M Digital Health Fund to Invest in Mid to Late-Stage Companies

by Fred Pennic 01/11/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

aMoon II

Israeli-based health tech and life sciences venture fund aMoon II has raised $600 million from investors and aims to raise up to $750 million by its close in February, Reuters reported. The fund’s objective is to generate strong investment returns by partnering with promising mid-late-stage companies in Israel and in select other global centers of healthtech innovation.

aMoon II Investment Focus

Founded in 2018,  aMoon II secured a $250 million investment commitment from Credit Suisse’s asset management and private banking divisions. The $600 million is up from the original target of $500 million for the venture fund and will focus on investing in mid to late-stage companies in biopharma, medical device, and digital health companies in Israel, the United States, and Europe. 

The fund intends to invest $10 million to $40 million in 15 to 20 companies over the next five years. In addition, the aMoon has launched a third fund, aMoon Velocity will focus on early-stage highly disruptive healthcare technologies, open exclusively to aMoon II investors. 

The fund is founded by Dr. Yair Schindel, its managing partner, and Marius Nacht, the billionaire co-founder of cybersecurity giant CheckPoint Software Technologies. Nacht is investing $360 million of his own money in the three funds. 

Portfolio Companies

aMoon II has invested in four companies to date, including cancer therapy firm Ayala Pharmaceuticals ($10.6M), antibody (Ab) drug development company Biolojic Design, medical device company CartiHeal; and radiology imaging analytics platform Zebra Medical Vision. 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: aMoon, Israeli digital health startups

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |